Authors
Benjamin Vesin, Ingrid Fert, Sylvain Ciret, Laëtitia Douguet, Fanny Moncoq, Amandine Noirat, Pierre Authié, Fabien Le Chevalier, Fabien Nevo, Catherine Blanc, Kirill Nemirov, Laleh Majlessi, Pierre Charneau
Published in
Molecular therapy. Oncology. Volume 34. Issue 3. Pages 201299. Sep 17, 2026. Epub Jul 18, 2026.
Abstract
Prostate cancer kills ≈350,000 yearly. While localized cases have 99% five-year survival, metastatic prostate cancer is hard to treat, with few options for tumors resistant to androgen deprivation. To leverage the immune system to fight prostate cancer, we developed a non-integrative lentiviral vector, namely "Lenti-PROST-02", which encodes clusters of T cell immunodominant regions of human prostatic acid phosphatase and prostate-specific antigen. Immunotherapy with Lenti-PROST-02 in a preclinical virulent prostate tumor model resulted in complete tumor eradication in vast majority of the treated animals. This antitumor effect was concomitant with induction of poly-functional CD8+ T splenocyte effectors against numerous T cell epitopes of the antigens encoded by Lenti-PROST-02, increased proportions of tumor-infiltrating CD8+ T cells with activated/differentiated/effector phenotype and a "cold-to-hot" inflammatory switch of the tumor microenvironment. Immunity induced by Lenti-PROST-02 was long-lasting and prevented tumor relapse. It was characterized by the persistence of CD44+ CD62L- CD127+ KLRG1- CD8+ memory T cells in secondary lymphoid organs, as well as an antigen-diversified memory response. Therefore, Lenti-PROST-02 therapeutic vaccine is a promising approach for prostate immuno-oncotherapy.
PMID:
42598525
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0